{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:28:12Z","timestamp":1791952092765,"version":"4.3.4"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.blre.2023.101162","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T21:35:53Z","timestamp":1702157753000},"page":"101162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Optimizing high dose melphalan"],"prefix":"10.1016","volume":"64","author":[{"given":"Gunjan","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2023.101162_bb0005","first-page":"6","article-title":"Cytotoxic alpha amino acids and endopeptidase","volume":"31","author":"Bergel","year":"1953","journal-title":"Br Emp Cancer Comp Annu"},{"key":"10.1016\/j.blre.2023.101162_bb0010","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1200\/JCO.1988.6.11.1768","article-title":"The systemic administration of intravenous melphalan","volume":"6","author":"Sarosy","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101162_bb0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty Years of melphalan use in hematopoietic stem cell transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101162_bb0020","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","article-title":"High-dose intravenous melphalan: a review","volume":"13","author":"Samuels","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101162_bb0025","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbmt.2004.03.001","article-title":"Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan:a phase I study","volume":"10","author":"Phillips","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101162_bb0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0005-2736(79)90217-7","article-title":"Cytotoxicity as an indicator for transport mechanism: evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell","volume":"550","author":"Vistica","year":"1979","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.blre.2023.101162_bb0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF00273521","article-title":"Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma","volume":"23","author":"Gera","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.blre.2023.101162_bb0040","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/BF00293997","article-title":"Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases","volume":"16","author":"Ardiet","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.blre.2023.101162_bb0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF00256174","article-title":"Pharmacokinetics of high-dose melphalan in children and adults","volume":"16","author":"Gouyette","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.blre.2023.101162_bb0050","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/BF00254244","article-title":"Renal clearance and protein binding of melphalan in patients with cancer","volume":"22","author":"Reece","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.blre.2023.101162_bb0055","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0277-5379(82)90006-2","article-title":"Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma","volume":"18","author":"Bosanquet","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.blre.2023.101162_bb0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2141.1987.tb06890.x","article-title":"Multiple myeloma treated with high dose intravenous melphalan","volume":"66","author":"Selby","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101162_bb0065","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2023.101162_bb0070","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V67.5.1298.1298","article-title":"High-dose melphalan with autologous bone marrow transplantation for multiple myeloma","volume":"67","author":"Barlogie","year":"1986","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2023.101162_bb0075","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1200\/JCO.1994.12.4.759","article-title":"High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma","volume":"12","author":"Cunningham","year":"1994","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2023.101162_bb0080","first-page":"A198","article-title":"Total therapy (TT) for newly diagnosed multiple myeloma","volume":"82","author":"Barlogie","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101162_bb0085","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2023.101162_bb0090","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.blre.2023.101162_bb0095","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"10192","key":"10.1016\/j.blre.2023.101162_bb0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.blre.2023.101162_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"The Lancet Haematology"},{"issue":"supplement 1","key":"10.1016\/j.blre.2023.101162_bb0110","first-page":"82","article-title":"Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2, Blood","volume":"138","author":"Avet Loiseau","year":"2021"},{"issue":"25","key":"10.1016\/j.blre.2023.101162_bb0115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, Lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101162_bb0120","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bcp.12906","article-title":"Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy","volume":"82","author":"Nath","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.blre.2023.101162_bb0125","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood.V82.7.2005.2005","article-title":"High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients","volume":"82","author":"Fermand","year":"1993","journal-title":"Blood"},{"issue":"8668","key":"10.1016\/j.blre.2023.101162_bb0130","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0140-6736(89)91552-3","article-title":"Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation","volume":"2","author":"Sheridan","year":"1989","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.blre.2023.101162_bb0135","first-page":"963","article-title":"Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma","volume":"15","author":"Harousseau","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101162_bb0140","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"Hematopoietic stem cell Transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.blre.2023.101162_bb0145","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/blood.V84.12.4278.bloodjournal84124278","article-title":"Early myeloablative therapy for multiple myeloma","volume":"84","author":"Alexanian","year":"1994","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101162_bb0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbmt.2014.10.023","article-title":"Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma","volume":"21","author":"Vij","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101162_bb0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41408-023-00864-0","article-title":"Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma","volume":"13","author":"Banerjee","year":"2023","journal-title":"Blood Cancer J"},{"issue":"16","key":"10.1016\/j.blre.2023.101162_bb0160","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/bloodadvances.2023009681","article-title":"Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy","volume":"7","author":"Charalampous","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2023.101162_bb0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10428194.2019.1646905","article-title":"vSalvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy","volume":"61","author":"Blocka","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2023.101162_bb0170","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbmt.2015.07.036","article-title":"Higher stem cell dose infusion after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis","volume":"22","author":"Shah","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2023.101162_bb0175","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3109\/10428194.2015.1121256","article-title":"Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation","volume":"57","author":"Landau","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2023.101162_bb0180","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bmt.1705471","article-title":"Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model","volume":"38","author":"Grazziutti","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101162_bb0185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/bmt.2008.299","article-title":"EBMT mucositis advisory group. The prospective Oral mucositis audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT","volume":"43","author":"McCann","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101162_bb0190","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/sj.bmt.1705384","article-title":"A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation","volume":"37","author":"Lilleby","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101162_bb0195","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/bmt.2016.207","article-title":"Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study","volume":"52","author":"Marchesi","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101162_bb0200","first-page":"2449","article-title":"Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines","volume":"28","author":"Correa","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.blre.2023.101162_bb0205","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41409-019-0468-6","article-title":"Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial","volume":"54","author":"Johansson","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2023.101162_bb0210","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/cpt.644","article-title":"Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial","volume":"102","author":"Cho","year":"2017","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/j.blre.2023.101162_bb0215","doi-asserted-by":"crossref","first-page":"22507","DOI":"10.1038\/s41598-021-02002-x","article-title":"Ice-cream used as cryotherapy during high-dose melphalan conditioning reduces oral mucositis after autologous hematopoietic stem cell transplantation","volume":"11","author":"Jasi\u0144ski","year":"2021","journal-title":"Sci Rep"},{"issue":"Suppl. 18","key":"10.1016\/j.blre.2023.101162_bb0220","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.seminoncol.2003.11.014","article-title":"Amifostine: is there evidence of tumor protection","volume":"30","author":"Koukourakis","year":"2003","journal-title":"Semin Oncol Suppl"},{"key":"10.1016\/j.blre.2023.101162_bb0225","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.bmt.1704946","article-title":"Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation","volume":"35","author":"Spencer","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2023.101162_bb0230","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1080\/10428194.2017.1408086","article-title":"Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma","volume":"59","author":"Malek","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.blre.2023.101162_bb0235","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/sj.bmt.1703757","article-title":"Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma","volume":"30","author":"Thieblemont","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101162_bb0240","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa040125","article-title":"Palifermin for oral mucositis after intensive therapy for hematologic cancers","volume":"351","author":"Spielberger","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2023.101162_bb0245","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/bmt.2012.257","article-title":"In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient\u2019s burden","volume":"48","author":"Blijlevens","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101162_bb0250","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1109\/JQE.1987.1073236","article-title":"Photobiological fundamentals of low-power laser therapy","volume":"23","author":"Karu","year":"1987","journal-title":"IEEE Journal of Quantum Electronics"},{"key":"10.1016\/j.blre.2023.101162_bb0255","first-page":"3969","article-title":"Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines","volume":"27","author":"Zadik","year":"2019","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.blre.2023.101162_bb0260","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/medicina59081413","article-title":"Low-level laser therapy for the treatment of Oral mucositis induced by hematopoietic stem cell Transplantation: a systematic review with Meta-analysis","volume":"59","author":"Franco","year":"2023","journal-title":"Medicina."},{"key":"10.1016\/j.blre.2023.101162_bb0265","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s10103-017-2211-0","article-title":"Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy","volume":"32","author":"Rodrigues","year":"2017","journal-title":"Lasers Med Sci"},{"issue":"12","key":"10.1016\/j.blre.2023.101162_bb0270","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/sj.bmt.1705664","article-title":"Symptom burden in patients undergoing autologous stem-cell transplantation","volume":"39","author":"Anderson","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2023.101162_bb0275","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/cncr.23299","article-title":"Symptom burden after autologous stem cell transplantation for multiple myeloma","volume":"112","author":"Campagnaro","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.blre.2023.101162_bb0280","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jpainsymman.2011.08.011","article-title":"Symptoms and quality of life in diverse patients undergoing hematopoietic stem cell transplantation","volume":"44","author":"Cohen","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.blre.2023.101162_bb0285","series-title":"Cancer Symptom Science: Measurement, Mechanisms, and Management","article-title":"High-dose therapy and posttransplantation symptom burden: striking a balance","volume":"224","author":"Giralt","year":"2010"},{"issue":"5","key":"10.1016\/j.blre.2023.101162_bb0290","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/1078-0432.CCR-13-2442","article-title":"Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation","volume":"20","author":"Wang","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.blre.2023.101162_bb0295","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1002\/cncr.34444","article-title":"A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation","volume":"128","author":"Scordo","year":"2022","journal-title":"Cancer."},{"issue":"11","key":"10.1016\/j.blre.2023.101162_bb0300","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/cncr.11382","article-title":"Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms","volume":"97","author":"Cleeland","year":"2003","journal-title":"Cancer."},{"issue":"6","key":"10.1016\/j.blre.2023.101162_bb0305","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2007.10.7805","article-title":"Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer","volume":"26","author":"Miller","year":"2008","journal-title":"JCO."},{"issue":"6","key":"10.1016\/j.blre.2023.101162_bb0310","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","article-title":"Interleukin-6 as a therapeutic target","volume":"21","author":"Rossi","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.blre.2023.101162_bb0315","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"San-Miguel","year":"2014","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101162_bb0320","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.4","article-title":"Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial","volume":"6","author":"Shah","year":"2016","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.blre.2023.101162_bb0325","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","article-title":"A phase I, open-label study of Siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease","volume":"19","author":"Kurzrock","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2023.101162_bb0330","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Voorhees","year":"2013","journal-title":"BJH."},{"issue":"3","key":"10.1016\/j.blre.2023.101162_bb0335","first-page":"S129","article-title":"Improved quality of life with Interleukin-6 (IL-6) blockade with Siltuximab Peri-autologous hematopoietic stem cell Transplantation (AHCT) in older patients with multiple myeloma (MM)","volume":"26","author":"Shah","year":"2020","journal-title":"BBMT."},{"key":"10.1016\/j.blre.2023.101162_bb0340","first-page":"657","article-title":"Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial","volume":"26","author":"Deng","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.blre.2023.101162_bb0345","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1002\/cam4.1690","article-title":"Programmed environmental illumination during autologous stem cell transplantation hospitalization for the treatment of multiple myeloma reduces severity of depression: a preliminary randomized controlled trial","volume":"7","author":"Valdimarsdottir","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2023.101162_bb0350","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/cncr.11842","article-title":"Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation: a randomized controlled trial","volume":"98","author":"Cassileth","year":"2003","journal-title":"Cancer."},{"issue":"9","key":"10.1016\/j.blre.2023.101162_bb0355","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.bbmt.2017.05.015","article-title":"Music therapy for symptom management after autologous stem cell Transplantation: results from a randomized study","volume":"23","author":"Bates","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101162_bb0360","first-page":"1","article-title":"Randomized phase 2 study of digital life coaching during transplantation for myeloma","volume":"25","author":"Banerjee","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.blre.2023.101162_bb0365","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/jcm10091841","article-title":"Treatment of multiple myeloma and the role of Melphalan in the era of modern therapies-current research and clinical approaches","volume":"10","author":"Poczta","year":"2021","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101162_bb0370","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbmt.2014.01.019","volume":"20","author":"Bubalo","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"10.1016\/j.blre.2023.101162_bb0375","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbmt.2011.05.005","article-title":"Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"17","author":"Vogl","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2023.101162_bb0380","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.bbmt.2019.12.707","article-title":"Successful personalization of propylene glycol free Melphalan (PGF-MEL) for multiple myeloma (MM) and AL amyloidosis (AL) patients undergoing autologous hematopoietic stem cell Transplant (AHCT) using pharmacokinetic (PK)-directed dosing","volume":"26","author":"Shah","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101162_bb0385","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2022-159357","volume":"140","author":"Straka","year":"2022","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101162_bb0390","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1046\/j.1365-2141.1996.d01-1932.x","article-title":"A pilot study of 220 mg\/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity","volume":"95","author":"Moreau","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101162_bb0395","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbmt.2004.03.001","article-title":"Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study","volume":"10","author":"Phillips","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101162_bb0400","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/bmt.2015.211","article-title":"A randomized study of melphalan 200mg\/m2 vs 280mg\/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT","volume":"51","author":"Bensinger","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101162_bb0405","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m 2 or 200 mg\/m 2 for autologous transplantation in myeloma: results from the collaboration to collect autologous Transplant outcomes in lymphoma and myeloma (CALM) study. A report by the EBMT ChronicMalignancies working party","volume":"103","author":"Auner","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101162_bb0410","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma","volume":"89","author":"Barlogie","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101162_bb0415","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101162_bb0420","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101162_bb0425","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2023.101162_bb0430","first-page":"401","article-title":"Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02\/HO95 study","volume":"130","author":"Cavo","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101162_bb0435","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous Transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101162_bb0440","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM)","author":"Hari","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.blre.2023.101162_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101929","article-title":"Multiple myeloma: role of autologous transplantation","volume":"82","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.blre.2023.101162_bb0450","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00280-003-0761-2","article-title":"Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies","volume":"53","author":"Mougenot","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.blre.2023.101162_bb0455","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-017-0581-x","article-title":"Population pharmacokinetics and optimal sampling strategy for model-based precision dosing of melphalan in patients undergoing hematopoietic stem cell transplantation","volume":"57","author":"Mizuno","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.blre.2023.101162_bb0460","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40262-021-01093-z","article-title":"Population pharmacokinetics of Melphalan in a large cohort of autologous and allogeneic hematopoietic cell Transplantation recipients: towards individualized dosing regimens","volume":"61","author":"Shah","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.blre.2023.101162_bb0465","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/S2352-3026(19)30023-7","article-title":"Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation formultiple myeloma: an open-label, randomised, phase 3 trial","volume":"6","author":"Bashir","year":"2019","journal-title":"Lancet Haematol"},{"issue":"19","key":"10.1016\/j.blre.2023.101162_bb0470","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/bloodadvances.2020002590","article-title":"Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM","volume":"4","author":"Saini","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2023.101162_bb0475","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12935-021-02313-z","article-title":"Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg\/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis","volume":"21","author":"Gao","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.blre.2023.101162_bb0480","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/stem.140351","article-title":"2\u2032,2\u2019-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA)","volume":"14","author":"Gruber","year":"1996","journal-title":"Stem Cells"},{"issue":"6","key":"10.1016\/j.blre.2023.101162_bb0485","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/S2352-3026(17)30080-7","article-title":"High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan","volume":"4","author":"Nieto","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.blre.2023.101162_bb0490","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101162_bb0495","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2005.03.2383","article-title":"Phase I\/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma","volume":"24","author":"Berenson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101162_bb0500","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"VISTA Trial Investigators Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101162_bb0505","first-page":"32","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)","volume":"115","author":"Roussel","year":"2010","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.blre.2023.101162_bb0510","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-10-1662","article-title":"A phase I\/II trial combining high-dose Melphalan and autologous Transplant with Bortezomib for multiple myeloma: a dose-and schedule-finding StudyMelphalan+ Bortezomib Conditioning for myeloma","volume":"16","author":"Lonial","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.blre.2023.101162_bb0515","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1182\/blood.2021014635","article-title":"Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study","volume":"139","author":"Roussel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101162_bb0520","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbmt.2018.01.036","article-title":"Phase 1\/2 trial of carfilzomib plus high-dose Melphalan preparative regimen for salvage autologous hematopoietic cell Transplantation followed by maintenance carfilzomib in patients with relapsed\/refractory multiple myeloma","volume":"24","author":"Costa","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.blre.2023.101162_bb0525","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1517\/14656566.2013.837885","article-title":"An old drug with a new future: bendamustine in multiple myeloma","volume":"14","author":"Gentile","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.blre.2023.101162_bb0530","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.bbmt.2013.02.013","article-title":"A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma","volume":"19","author":"Mark","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101162_bb0535","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41409-019-0587-0","article-title":"High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma","volume":"54","author":"Gomez-Arteaga","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101162_bb0540","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/bmt.2016.94","article-title":"A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy","volume":"51","author":"Martino","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.blre.2023.101162_bb0545","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41409-022-01681-y","article-title":"Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: a randomized phase-2 trial","volume":"57","author":"Farag","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2023.101162_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.05.022","article-title":"High-dose Bendamustine, etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning before autologous Transplantation for patients with multiple myeloma","volume":"28","author":"Solomon","year":"2022","journal-title":"Transplantation and cellular Therapy"},{"key":"10.1016\/j.blre.2023.101162_bb0555","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.bbmt.2015.08.026","article-title":"A phase IIb, multicenter, open-label, safety, and efficacy study of high-dose, propylene glycol-free melphalan hydrochloride for injection (EVOMELA) for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation","volume":"21","author":"Hari","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2023.101162_bb0560","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jtct.2022.02.014","article-title":"A review of propylene glycol-free melphalan conditioning for hematopoietic cell transplantation for multiple myeloma and light chain amyloidosis","volume":"28","author":"Hari","year":"2022","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.blre.2023.101162_bb0565","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.bbmt.2018.04.028","article-title":"Pharmacokinetics of high-dose propylene glycol\u2013free melphalan in multiple myeloma patients undergoing autologous hematopoietic cell transplantation","volume":"24","author":"Dhakal","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.blre.2023.101162_bb0570","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bbmt.2008.09.019","article-title":"Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial","volume":"14","author":"Qazilbash","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2023.101162_bb0575","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood-2002-10-3250","article-title":"166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1\/2 trials","volume":"102","author":"Giralt","year":"2003","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2023.101162_bb0580","first-page":"ECR36","article-title":"Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma","volume":"89","author":"Knop","year":"2004","journal-title":"Haematologica."},{"issue":"2","key":"10.1016\/j.blre.2023.101162_bb0585","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S2352-3026(22)00002-3","article-title":"Melflufen for multiple myeloma: a promise unfulfilled?","volume":"9","author":"Prashant","year":"2022","journal-title":"The Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101162_bb0590","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bbmt.2020.03.008","article-title":"PARP inhibition synergizes with Melphalan but does not reverse resistance completely","volume":"25","author":"Patel","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.blre.2023.101162_bb0595","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/jcm10091841","article-title":"Treatment of multiple myeloma and the role of Melphalan in the era of modern therapies-current research and clinical approaches","volume":"10","author":"Poczta","year":"2021","journal-title":"J Clin Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:30:11Z","timestamp":1759437011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23001327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":119,"alternative-id":["S0268960X23001327"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101162","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing high dose melphalan","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101162"}}